National Network of Depression Centers position statement: Insurance coverage for intravenous ketamine in treatment-resistant major depressive disorder

Affiliations

• ¹ University of Iowa Health Care, Department of Psychiatry/Iowa Neuroscience Institute, Iowa City, IA 52242, USA. Electronic address: mark-niciu@uiowa.edu.
• ² McLean Hospital, Psychiatric Neurotherapeutics Program, 115 Mill St., Belmont, MA 02478, USA; Harvard Medical School, Department of Psychiatry, Boston, MA 02115, USA.
• ³ University of Florida College of Medicine, Department of Psychiatry, Gainesville, FL 32610, USA.
• ⁴ University of Louisville School of Medicine, Department of Psychiatry and Behavioral Sciences, Louisville, KY 40202, USA.
• ⁵ Kadima Neuropsychiatry Institute, La Jolla, CA 92037, USA; University of California San Diego School of Medicine, La Jolla, CA 92093, USA.
• ⁶ Mira Pharmaceuticals, Baltimore, MD 21205, USA; The Johns Hopkins School of Medicine, Department of Psychiatry and Behavioral Sciences, Baltimore, MD 21205, USA.
• ⁷ University of Utah School of Medicine, Department of Psychiatry, University Neuropsychiatric Institute, Salt Lake City, UT 84132, USA.
• ⁸ The Johns Hopkins School of Medicine, Department of Psychiatry and Behavioral Sciences, Baltimore, MD 21205, USA.
• ⁹ University of Colorado Anschutz Medical Campus, Department of Psychiatry, Helen and Arthur E. Johnson Depression Center, Aurora, CO 80045, USA.
• ¹⁰ Mayo Clinic, Department of Psychiatry and Psychology, Rochester, MN 55905, USA.
• ¹¹ University of Michigan School of Medicine, Department of Psychiatry and Depression Center, Ann Arbor, MI 48109, USA.